Discover the Future of Antibody/TCR-based Therapeutics: Meet Biocytogen’s Licensing Team at BIO-EUROPE 2023!
Biocytogen will be exhibiting and hosting 1-on-1 meetings at BIO-EUROPE 2023, taking place from November 6-8, 2023 in Munich, Germany. Biocytogen is thrilled to be part of this premier event, showcasing our latest innovations in clinical and preclinical therapeutic asset discovery and development. Here’s how to connect with us at the event: Booth #60: Connect […]
Webinar: Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies
Our webinar “Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies” was live at 12:00 PM EST on Nov 14th, 2023. About the webinar: Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is […]
Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti- CD40 mAb) Phase I Trial at ESMO 2023
October 16, 2023
Beijing, China, Oct 16, 2023 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), will attend and present a poster at the ESMO Congress 2023, taking place in Madrid, Spain from October 20-24, 2023. The poster will summarize data from a completed phase I study of YH003, an […]
Visit our Booth and Bispecific ADC Posters at World ADC San Diego: Oct 17-18
Biocytogen’s BD team is excited to exhibit and attend the 14th Annual World ADC San Diego conference, taking place from Oct 17–18, 2023! Be sure to visit booth 23 to speak with our team members, and check out our posters highlighting 2 of our bispecific ADC assets: Poster #10: Potent efficacy in mice and favorable […]
Webinar: Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo
October 4, 2023
Our webinar “Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo” was live at 12:00 PM EDT on Oct 25th, 2023. About the webinar: Therapeutics targeting the immune system for oncology applications (such as immune checkpoint inhibitors, or ICIs) can in some cases lead to adverse effects in patients, […]
Join us at the Festival of Biologics Europe 2023: Oct 10-12
Join us at the Festival of Biologics Europe 2023 in Basel, Switzerland from Oct 10-12! Stop by booth #703 and learn about our preclinical animal models and state-of-the-art services, ranging from antibody discovery to pharmacology evaluation services. Attend the meeting Talk to us at booth 703! The Festival of Biologics is the meeting place for […]
Complimentary Pair of Genetically Modified Mice – Valentine’s Day Special Offer
October 1, 2023
This Valentines day, receive a complimentary breeding pair of genetically modified mice with Biocytogen’s gene targeting services. Hurry up– our offer is valid only until 2/14/2024 with code “FREECOUPLE”. Seize the opportunity to get started on your gene editing project now! Our Platform Our Extreme Genome Editing (EGETM) platform has empowered us to specialize in […]
Don’t Miss Our Presentation and Booth at BioJapan 2023!
September 26, 2023
Biocytogen’s Asia-Pacific business development team is pleased to present and exhibit at BioJapan 2023, taking place from October 11-13, 2023 in Yokohama, Japan! Dr. Jie Xiang, BD Director of the Asia-Pacific region, will be delivering an oral presentation at 15:30-16:30, Wednesday, October 11, entitled “Accelerating Antibody-Based Therapeutics Development: Leveraging Biocytogen’s Innovative RenMice, Proprietary mAb/BsAb/TCR-m/Nanobody/BsADC Assets, […]
Biocytogen Officially Launches RenMice® Series
September 15, 2023
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen’s Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property. […]
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
September 7, 2023
Beijing, China, September 7, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of […]
